KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Long-Term Debt Repayments (2018)

Arbutus Biopharma's Long-Term Debt Repayments history spans 2 years, with the latest figure at -$12.0 million for Q4 2019.

  • For Q4 2019, Long-Term Debt Repayments changed N/A year-over-year to -$12.0 million; the TTM value through Dec 2019 reached -$12.0 million, changed N/A, while the annual FY2018 figure was $12.0 million, N/A changed from the prior year.
  • Long-Term Debt Repayments for Q4 2019 was -$12.0 million at Arbutus Biopharma, down from $12.0 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $12.0 million in Q1 2018 and bottomed at -$12.0 million in Q4 2019.